Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
Abrysvo, ADC, adversarial, AKS, Alexandre, Alexion, allosteric, analgesia, analyst, anesthesia, artificial, assembled, asterisk, attention, awaiting, background, BCR, belief, biased, biochemical, Blackstone, blaylock, bone, Boshoff, Bravo, BRCA, broadly, cap, Castle, catastrophic, ceiling, celebrate, cervical, chart, Chase, circulating, CISO, clarity, colorectal, combo, confirmatory, contemplation, controversial, COVID, crime, crucial, cultivate, cybersecurity, dan, de, deficient, deflation, depth, difficulty, disaster, Disitamab, donut, EAP, echevarria, ecosystem, Elrexfio, embedded, empowerment, endemic, enfortumab, enterprise, ERM, expedite, fitelparvovec, flawed, fluoropyrimidine, footnote, gastrointestinal, Genevant, genitourinary, Genmab, Germay, giroctocogene, graft, gynecological, harnessing, Healthier, helen, hematologic, HRR, HRSA, Hungary, Ignite, importantly, inappropriate, incentivize, inconsistency, Indenture, inefficiency, Inline, inoperable, instance, intelligence, intranasal, intrusion, irrevocably, Israeli, joseph, JPMorgan, Kepro, kinase, licensee, licensure, lifecycle, Linkbase, Litfulo, littman, Lucira, madden, Majorelle, Manhattan, margaret, Mellon, misuse, morale, Mount, mutual, nasal, navigate, NC, Ngenla, nmCSPC, Nonfunded, Nordisk, Novo, OECD, OIG, OMI, omnichannel, opportunistic, ORD, overseeing, oxaliplatin, Padcev, page, pembrolizumab, penetration, PIE, Pillar, pledged, Poland, poor, PRD, priority, prompt, protocol, ransomware, recessionary, recombination, recurrence, recurrent, RemeGen, remuneration, rephasing, Republic, retaliation, retention, revolutionizing, Rocky, Romania, ronald, rotation, RSV, satisfaction, Schema, scrutinize, Seagen, seasonal, secondary, sense, signature, singly, smith, SMPA, Somavert, spray, stockpile, streamlining, struggling, Sumitomo, surface, suspected, syndrome, Synthon, Takeda, Taxonomy, Telavant, thoracic, tisotumab, Tivdak, toolkit, tornado, touch, training, Transplant, trastuzumab, triage, true, tucatinib, Tukysa, tyrosine, ULC, Ulcerative, unaudited, unconditionally, unconsolidated, underinsured, undersigned, underway, unidentified, uninsured, unintended, uninterrupted, unveiled, upcoming, urology, urothelial, utmost, vast, vedotin, Velsipity, Vepdegestrant, Vigilance, XBRL, Zai, Zavzpret
Removed:
accommodate, accruing, Anacor, Angela, antibody, Asian, Aug, automation, bioequivalence, bioequivalent, Biogen, buyer, castration, center, CMA, convertible, CStone, Dec, denominated, derecognition, derecognized, direction, disgorgement, disputed, distributed, domestically, enforced, ethically, Eucrisa, evenly, eventual, Feb, fiduciary, Glenmark, great, headquartered, Hwang, indirect, Jan, methodology, Myovant, NASDAQ, neighborhood, Nexium, Nov, NRDL, obligor, Oct, officially, oncological, ordered, originator, Overnight, par, Parcel, pause, payer, Peapack, perpetual, prevalent, proposing, prospectively, protease, proton, Protonix, PTSRU, pump, reallocated, reallocating, redeem, redeploy, renamed, repay, repurchased, restitution, Retacrit, RSC, Secured, separated, simplify, SOFR, Spiral, sugemalimab, superseded, Sutent, transformed, travel, treating, underwritten, unified, University, vaccinated, venture, widespread, William, WPP
Filing tables
Filing exhibits
Related press release
Associated PFE transcripts
PFE similar filings
Filing view
External links
EXHIBIT 22
Subsidiary Issuers of Guaranteed Securities
As of December 31, 2023, Pfizer Inc. (Parent Guarantor) was the unconditional and irrevocable guarantor of the following unsecured registered notes issued by wholly-owned subsidiaries of Parent Guarantor:
Name of Subsidiary Issuer | State of Formation of Issuer | Description of Registered Notes | ||||||
Wyeth LLC | Delaware | 6.45% Notes due 2024 | ||||||
Pharmacia LLC | Delaware | 6.75% Debentures due 2027 | ||||||
Pharmacia LLC | Delaware | 6.60% Debentures due 2028 | ||||||
Wyeth LLC | Delaware | 6.50% Notes due 2034 | ||||||
Wyeth LLC | Delaware | 6.00% Notes due 2036 | ||||||
Wyeth LLC | Delaware | 5.95% Notes due 2037 | ||||||
Pfizer Investment Enterprises Pte. Ltd. | Republic of Singapore | 4.650% Notes due 2025 | ||||||
Pfizer Investment Enterprises Pte. Ltd. | Republic of Singapore | 4.450% Notes due 2026 | ||||||
Pfizer Investment Enterprises Pte. Ltd. | Republic of Singapore | 4.450% Notes due 2028 | ||||||
Pfizer Investment Enterprises Pte. Ltd. | Republic of Singapore | 4.650% Notes due 2030 | ||||||
Pfizer Investment Enterprises Pte. Ltd. | Republic of Singapore | 4.750% Notes due 2033 | ||||||
Pfizer Investment Enterprises Pte. Ltd. | Republic of Singapore | 5.110% Notes due 2043 | ||||||
Pfizer Investment Enterprises Pte. Ltd. | Republic of Singapore | 5.300% Notes due 2053 | ||||||
Pfizer Investment Enterprises Pte. Ltd. | Republic of Singapore | 5.340% Notes due 2063 |